Q1 2026 13F · SEC CIK 2092021
Seven Fleet Capital Management LP
Hedge fundFiled 2026-06-04 for Q1 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $318.3M
- Reported positions
- 115
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $434.6M
Seven Fleet Capital Management LP is a hedge fund that reported 115 positions worth $318.3M in its Q1 2026 13F, filed 2026-06-04. Its largest holdings were Cg Oncology Inc (30.6%), Tango Therapeutics Inc (TNGX, 3.3%), Revolution Medicines Inc (RVMD, 2.5%).
Seven Fleet Capital Management LP holdings largest 50 of 115 positions.
Weights are shares of the filer's total reported 13F value, compared with Q4 2025. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| 156944101Cg Oncology Inc | 30.6% | — | $97.4M |
| TNGXTango Therapeutics Inc | 3.3% | +133.3% | $10.5M |
| RVMDRevolution Medicines Inc | 2.5% | +22.8% | $7.9M |
| TYRATyra Biosciences Inc | 2.4% | +146.0% | $7.5M |
| LQDALiquidia Corporation | 2.2% | +105.9% | $7.1M |
| AGIOAgios Pharmaceuticals Inc | 2.2% | +560.2% | $7.1M |
| IPSCCentury Therapeutics Inc | 2.1% | — | $6.7M |
| ELVNEnliven Therapeutics Inc | 2.0% | +64.1% | $6.4M |
| PCVXVaxcyte Inc | 2.0% | +327.6% | $6.3M |
| 87583X110Tango Therapeutics Inc | 2.0% | — | $6.3M |
| COGTCogent Biosciences Inc | 1.8% | -30.2% | $5.8M |
| 05338F307Avalo Therapeutics Inc | 1.7% | — | $5.4M |
| 603380206Minerva Neurosciences Inc | 1.7% | — | $5.4M |
| CGONCg Oncology Inc | 1.6% | -95.0% | $5.1M |
| PHVSPharvaris N V | 1.5% | +212.1% | $4.9M |
| ABVXAbivax SA | 1.5% | +218.9% | $4.8M |
| DNTHDianthus Therapeutics Inc | 1.4% | +270.3% | $4.6M |
| N69605109Pharvaris N V | 1.3% | — | $4.1M |
| CYTKCytokinetics Inc | 1.3% | +492.8% | $4.0M |
| SLNOSoleno Therapeutics Inc | 1.2% | -11.0% | $3.9M |
| 29337E103Enliven Therapeutics Inc | 1.2% | — | $3.7M |
| ERASErasca Inc | 1.1% | — | $3.6M |
| ROIVRoivant Sciences Ltd | 1.1% | — | $3.6M |
| 23284F106Cytomx Therapeutics Inc. | 1.1% | — | $3.4M |
| AVTXAvalo Therapeutics Inc | 1.0% | +237.6% | $3.2M |
| 15673T101Century Therapeutics Inc | 1.0% | — | $3.2M |
| EPRXEupraxia Pharmaceuticals Inc | 1.0% | — | $3.1M |
| IDYAIdeaya Biosciences Inc | 0.9% | — | $2.9M |
| TSHATaysha Gene Therapies Inc | 0.9% | +274.2% | $2.8M |
| 04351P101Ascendis Pharma A/s | 0.9% | +114.8% | $2.8M |
| CMPXCompass Therapeutics Inc | 0.9% | -9.1% | $2.7M |
| GLTODamora Therapeutics Inc | 0.8% | — | $2.6M |
| KALVKalvista Pharmaceuticals Inc | 0.8% | +165.4% | $2.6M |
| RLAYRelay Therapeutics Inc | 0.8% | +253.1% | $2.6M |
| AXSMAxsome Therapeutics Inc. | 0.7% | +8.5% | $2.4M |
| 20454B105Compass Therapeutics Inc | 0.7% | — | $2.2M |
| 252828109Dianthus Therapeutics Inc | 0.7% | — | $2.2M |
| 29842P106Eupraxia Pharmaceuticals Inc | 0.6% | — | $2.0M |
| 24477V105Definium Therapeutics Inc | 0.6% | — | $1.9M |
| MLYSMineralys Therapeutics Inc | 0.6% | +65.5% | $1.9M |
| SLNOSoleno Therapeutics Inc | 0.6% | — | $1.8M |
| MDGLMadrigal Pharmaceuticals Inc | 0.6% | +82.4% | $1.8M |
| CTMXCytomx Therapeutics Inc. | 0.5% | — | $1.7M |
| LONALeonabio Inc | 0.5% | +28.7% | $1.7M |
| SVRASavara Inc | 0.5% | — | $1.6M |
| CATXPerspective Therapeutics Inc | 0.5% | — | $1.6M |
| ASMBAssembly Biosciences Inc. | 0.5% | -23.9% | $1.6M |
| 78397T203Sab Biotherapeutics Inc | 0.5% | — | $1.5M |
| NERVMinerva Neurosciences Inc | 0.5% | — | $1.5M |
| ZLABZai Lab Ltd | 0.5% | — | $1.5M |
What Seven Fleet Capital Management LP bought and sold in Q1 2026, against Q4 2025.
New positions
Q4 2025's filing was too long to tell new positions apart.
Added to
- AGIO Agios Pharmaceuticals Inc+560.2% shares
- CYTK Cytokinetics Inc+492.8% shares
- PCVX Vaxcyte Inc+327.6% shares
- TSHA Taysha Gene Therapies Inc+274.2% shares
- DNTH Dianthus Therapeutics Inc+270.3% shares
- RLAY Relay Therapeutics Inc+253.1% shares
- AVTX Avalo Therapeutics Inc+237.6% shares
- ABVX Abivax SA+218.9% shares
Reduced
- CGON Cg Oncology Inc-95.0% shares
- COGT Cogent Biosciences Inc-30.2% shares
- ASMB Assembly Biosciences Inc.-23.9% shares
- SLNO Soleno Therapeutics Inc-11.0% shares
- CMPX Compass Therapeutics Inc-9.1% shares
Left the top 50
- TERN Terns Pharmaceuticals Incwas 3.6%
- EXEL Exelixis Incwas 2.0%
- XNCR Xencor Incwas 1.1%
- BLTE Belite Bio Incwas 1.0%
- DYN Dyne Therapeutics Incwas 0.9%
- NUVL Nuvalent Incwas 0.9%
- FOLD Amicus Therapeuticwas 0.8%
- IKT Inhibikase Therapeutics Incwas 0.7%
Share counts compared with the Q4 2025 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q1 2026 | $318.3M | 115 |
| Q4 2025 | $147.8M | 85 |
Questions about Seven Fleet Capital Management LP's portfolio
What stocks does Seven Fleet Capital Management LP own?
Seven Fleet Capital Management LP's latest 13F, for Q1 2026 and filed Jun 4, 2026, lists 115 positions worth $318.3M. The largest are Cg Oncology Inc at 30.6%, Tango Therapeutics Inc (TNGX) at 3.3%, Revolution Medicines Inc (RVMD) at 2.5%, Tyra Biosciences Inc (TYRA) at 2.4% and Liquidia Corporation (LQDA) at 2.2%.
What did Seven Fleet Capital Management LP buy last quarter?
In Q1 2026, Seven Fleet Capital Management LP added Agios Pharmaceuticals Inc (AGIO) (+560.2% shares), Cytokinetics Inc (CYTK) (+492.8% shares) and Vaxcyte Inc (PCVX) (+327.6% shares), compared with its Q4 2025 filing.
What did Seven Fleet Capital Management LP sell last quarter?
In Q1 2026, Seven Fleet Capital Management LP cut from its top 50 Terns Pharmaceuticals Inc (TERN), cut from its top 50 Exelixis Inc (EXEL), cut from its top 50 Xencor Inc (XNCR), cut from its top 50 Belite Bio Inc (BLTE), cut from its top 50 Dyne Therapeutics Inc (DYN), Cg Oncology Inc (CGON) (-95.0% shares), Cogent Biosciences Inc (COGT) (-30.2% shares) and Assembly Biosciences Inc. (ASMB) (-23.9% shares), compared with its Q4 2025 filing.
When is Seven Fleet Capital Management LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Seven Fleet Capital Management LP's filing for the quarter ending Jun 30, 2026 was due by Aug 14, 2026; this page updates once it is processed.
How much money does Seven Fleet Capital Management LP manage?
Seven Fleet Capital Management LP reported $434.6M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $318.3M.